Connect Sign In
Lung Cancer Mutation Panel
Ordering Recommendation
Recommended test to detect mutations in BRAF, EGFR, ERBB2, KRAS, and MET genes in non-small cell lung cancer (NSCLC) to determine patient eligibility for targeted therapy. Additional molecular testing should be considered for detection of gene rearrangements. This test detects only canonical variants resulting in MET exon 14 skipping; additional testing should be considered if more comprehensive evaluation is desired.
New York DOH Approval Status
Specimen Required
Tumor tissue
Tumor Tissue: Formalin fix (10 percent neutral buffered formalin, not decalcified) and paraffin embedded tissue with at least 20 percent tumor burden. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 8 unstained 5 micron slides. (Min: 5 slides).
Transport block and/or slide(s) in a tissue transport kit (ARUP Supply # 47808) available online through eSupply using ARUP Connect or contact ARUP Client Services at 800-522-2787.
New York State Clients: Transport tissue (Formalin-fixed, paraffin embedded) or 10 unstained, nonbaked slides and 1 slide stained with hematoxylin and eosin .
Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Less than 20 percent tumor. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens (except in EDTA). Decalcified specimens in EDTA will require a client approved disclaimer.
Include surgical pathology report.
If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
Our pathologists will review every case to determine if there is an adequate tumor area for testing. Submitted specimens should contain >20 percent tumor. Specimens may be canceled, and a new block requested if there is not an acceptable area for extraction or if block/tissue has been decalcified (except in EDTA).
Samples that produce less than the optimal concentration of DNA input and/or samples decalcified in EDTA will require a disclaimer for testing or be canceled.
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-15 days
Reference Interval
Interpretive Data
Laboratory Developed Test (LDT)
Note
Hotspots Tested: BRAF (NM_004333) exon 15; EGFR (NM_005228) exons 18, 19, 20, 21; ERBB2 (NM_004448) exons 8, 19, 20; KRAS (NM_004985) exons 2, 3, 4; MET (NM_001127500) exons 14, 15. See Additional Technical Information for more information.
Hotline History
Hotline History
CPT Codes
81445, 81235, 81210, 81275, 81276
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2002148 | Block ID | 57723-9 |
| 3017503 | Lung Mut Int | 102042-9 |
Aliases
- Non-small cell lung cancer
- NSCLC
